ValiRx plc (AIM:VAL)

Market Cap	1.78M
Revenue (ttm)	9.60K
Net Income (ttm)	-1.97M
Shares Out	374.35M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,382,546
Average Volume	3,277,874
Open	0.4875
Previous Close	0.5000
Day's Range	0.4500 - 0.5100
52-Week Range	0.3750 - 4.4890
Beta	0.10
RSI	34.21
Earnings Date	Apr 25, 2025

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 16
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL